Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Choosing the right rewards program can significantly impact your benefits. Learn which one suits you best.
27,839 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Global markets reel after a Supreme Court ruling narrows the Trump-era tariff framework, prompting emergency meetings...
Joby Aviation is set to report Q4 2025 results after the close, and the focal point for investors is cash burn. The c...
Unpack the essentials of fulgent genetics (flgt) earnings in plain language. This guide translates the earnings trans...
Harvard Management Company disclosed a strategic reallocation of its crypto portfolio, trimming Bitcoin ETF exposure ...
A premium fitness brand attracts a substantial fund investment while its stock lags. This piece breaks down what it m...
Howard Hanna NYC appoints Hal Gavzie as executive director of business development, signaling a bold push to expand i...
SpaceX’s planned IPO could force immediate inclusion in Nasdaq-100 ETFs, igniting volatility for QQQ and other tracke...
A dramatic 72% decline in a key internet infrastructure stock drew a bold $12 million investment. This article explai...
EVgo’s growth hinges on expanding its fast-charging network and capitalizing on policy support. This article outlines...
Gold back under $5,000 has traders weighing the next ETF move. This report compares key gold ETFs, costs, and what co...
The pandemic reshaped Americans' trust in science and altered how households save, spend, and invest. This report out...